Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
ARLINGTON, Va., Jan. 13 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, The Contract Research Market for Drug Discovery Technologies: Opportunities for...
CHICAGO, Jan. 11 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for GOOG, UPS, ANF, MUR, and LIFE. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- GenVault Corporation (Carlsbad, CA) today announces a supply and resale agreement with Life Technologies Corporation (NASDAQ:LIFE), under which Life...
ARLINGTON, Va., Dec. 1 /PRNewswire/ -- BioInformatics, LLC announces the release of its newest report, The Market Outlook for Research Products in FY2010. The 8.2 billion dollars appropriated to...
ARLINGTON, Va., Sept. 10 /PRNewswire/ -- BioInformatics, LLC (http://www.gene2drug.com/), the premier research and advisory firm serving the life science market, announces the pending release of...
WASHINGTON, Sept. 2 /PRNewswire-FirstCall/ -- Danaher Corporation (NYSE: DHR) today announced that it has signed a definitive agreement with MDS Inc. (TSX: MDS; NYSE: MDZ) to acquire the...
FORT WORTH, Texas, Aug. 4 /PRNewswire-USNewswire/ -- Of the 600,000-800,000 people trafficked across international borders each year, 50 percent are under 17. It is estimated that by 2010, human...
CHICAGO, July 2 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
